Under the terms of the ten year agreement, Akorn will be responsible for the manufacturing and supply of several injectable drug products. Akorn anticipates annual contract revenue from these products to be in the range of $4 million to $5 million, over the life of the supply agreement.
Arthur Przybyl, president and CEO of Akorn, said: “This agreement reflects Akorn’s commitment to providing high quality contract manufacturing services to the pharmaceutical industry. We look forward to supplying these important drug products from our Decatur, Illinois facility.”